Agilent Technologies (NYSE:A) Price Target Raised to $175.00

Key Points

• Goldman Sachs raised Agilent Technologies’ price target to $175 from $155 and maintained a “buy” rating, implying about 11.3% upside. The broader analyst consensus is “Moderate Buy,” with an average target of $170.33.
• Agilent exceeded quarterly expectations, reporting $1.88 billion in revenue and adjusted EPS of $1.62, up from $1.37 a year earlier. The company also issued fiscal 2026 adjusted EPS guidance of $6.18–$6.21.
• Shares rose 1.4% to $157.22, while institutional investors and hedge funds own 87.41% of the stock. Several brokerages, including RBC, Stifel and Bernstein, also raised their price targets following the results.

Agilent Technologies (NYSE:A - Get Free Report) had its target price upped by equities research analysts at The Goldman Sachs Group from $155.00 to $175.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the medical research company's stock. The Goldman Sachs Group's price target would indicate a potential upside of 11.31% from the company's current price.

Several other brokerages also recently commented on A. Stifel Nicolaus upped their price target on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a "buy" rating in a research report on Thursday. Sanford C. Bernstein increased their target price on Agilent Technologies from $155.00 to $180.00 and gave the company an "outperform" rating in a report on Thursday. Barclays raised their target price on Agilent Technologies from $150.00 to $175.00 and gave the stock an "overweight" rating in a research report on Thursday. HSBC lowered their price target on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Wednesday, June 3rd. Finally, Royal Bank Of Canada increased their price objective on Agilent Technologies from $155.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $170.33.

Agilent Technologies Trading Up 1.4%

Shares of NYSE A traded up $2.13 during mid-day trading on Thursday, hitting $157.22. 1,992,931 shares of the company traded hands, compared to its average volume of 2,232,849. The business has a 50 day moving average of $139.16 and a two-hundred day moving average of $126.65. The stock has a market capitalization of $44.40 billion, a price-to-earnings ratio of 31.56, a PEG ratio of 2.73 and a beta of 1.25. Agilent Technologies has a 1 year low of $108.35 and a 1 year high of $163.75. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The firm had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the previous year, the company earned $1.37 EPS. The business's revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, sell-side analysts anticipate that Agilent Technologies will post 6.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds have recently modified their holdings of the stock. Amundi raised its holdings in shares of Agilent Technologies by 20.3% during the second quarter. Amundi now owns 1,294,098 shares of the medical research company's stock worth $171,891,000 after acquiring an additional 218,514 shares in the last quarter. HighTower Advisors LLC grew its stake in Agilent Technologies by 3.3% in the second quarter. HighTower Advisors LLC now owns 176,828 shares of the medical research company's stock valued at $23,488,000 after purchasing an additional 5,710 shares in the last quarter. California State Teachers Retirement System grew its stake in Agilent Technologies by 12,343.3% in the second quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company's stock valued at $7,249,471,000 after purchasing an additional 54,138,451 shares in the last quarter. Wedmont Private Capital increased its position in Agilent Technologies by 10.8% in the 2nd quarter. Wedmont Private Capital now owns 5,599 shares of the medical research company's stock worth $752,000 after purchasing an additional 547 shares during the last quarter. Finally, HB Wealth Management LLC increased its position in Agilent Technologies by 39.1% in the 2nd quarter. HB Wealth Management LLC now owns 20,878 shares of the medical research company's stock worth $2,773,000 after purchasing an additional 5,874 shares during the last quarter. 87.41% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source